WGS Valuation

GeneDx Holdings Corp

Add to Watchlist

Advanced Chart

129.490

+0.49(0.380%)1D

Overview
Forecast
Valuation
Earnings

WGS Relative Valuation

WGS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, WGS is overvalued; if below, it's undervalued.

Historical Valuation

GeneDx Holdings Corp (WGS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 8.27 is considered Overvalued compared with the five-year average of 8.79. The fair price of GeneDx Holdings Corp (WGS) is between 67.94 to 100.51 according to relative valuation methord. Compared to the current price of 129.00 USD , GeneDx Holdings Corp is Overvalued By 28.35%.

Relative Value

Fair Zone

67.94-100.51

Current Price：129.00

28.35%

Overvalued

62.50

Trailing

Forward

47.75

EV/EBITDA

GeneDx Holdings Corp. (WGS) has a current EV/EBITDA of 47.75. The 5-year average EV/EBITDA is -107.08. The thresholds are as follows: Strongly Undervalued below -928.96, Undervalued between -928.96 and -518.02, Fairly Valued between 303.86 and -518.02, Overvalued between 303.86 and 714.80, and Strongly Overvalued above 714.80. The current Forward EV/EBITDA of 47.75 falls within the Historic Trend Line -Fairly Valued range.

52.69

EV/EBIT

GeneDx Holdings Corp. (WGS) has a current EV/EBIT of 52.69. The 5-year average EV/EBIT is -4.77. The thresholds are as follows: Strongly Undervalued below -119.03, Undervalued between -119.03 and -61.90, Fairly Valued between 52.36 and -61.90, Overvalued between 52.36 and 109.49, and Strongly Overvalued above 109.49. The current Forward EV/EBIT of 52.69 falls within the Overvalued range.

8.26

GeneDx Holdings Corp. (WGS) has a current PS of 8.26. The 5-year average PS is 17.56. The thresholds are as follows: Strongly Undervalued below -63.30, Undervalued between -63.30 and -22.87, Fairly Valued between 57.99 and -22.87, Overvalued between 57.99 and 98.42, and Strongly Overvalued above 98.42. The current Forward PS of 8.26 falls within the Historic Trend Line -Fairly Valued range.

69.46

P/OCF

GeneDx Holdings Corp. (WGS) has a current P/OCF of 69.46. The 5-year average P/OCF is -1079.43. The thresholds are as follows: Strongly Undervalued below -11600.28, Undervalued between -11600.28 and -6339.86, Fairly Valued between 4180.99 and -6339.86, Overvalued between 4180.99 and 9441.41, and Strongly Overvalued above 9441.41. The current Forward P/OCF of 69.46 falls within the Historic Trend Line -Fairly Valued range.

39.42

P/FCF

GeneDx Holdings Corp. (WGS) has a current P/FCF of 39.42. The 5-year average P/FCF is 4.66. The thresholds are as follows: Strongly Undervalued below -24.86, Undervalued between -24.86 and -10.10, Fairly Valued between 19.42 and -10.10, Overvalued between 19.42 and 34.17, and Strongly Overvalued above 34.17. The current Forward P/FCF of 39.42 falls within the Strongly Overvalued range.

GeneDx Holdings Corp (WGS) has a current Price-to-Book (P/B) ratio of 13.36. Compared to its 3-year average P/B ratio of 3.80 , the current P/B ratio is approximately 252.12% higher. Relative to its 5-year average P/B ratio of 2.81, the current P/B ratio is about 374.94% higher. GeneDx Holdings Corp (WGS) has a Forward Free Cash Flow (FCF) yield of approximately 0.02%. Compared to its 3-year average FCF yield of -109.32%, the current FCF yield is approximately -100.02% lower. Relative to its 5-year average FCF yield of -73.98% , the current FCF yield is about -100.03% lower.

13.41

P/B

Median3y

3.80

Median5y

2.81

0.02

FCF Yield

Median3y

-109.32

Median5y

-73.98

Competitors Valuation Multiple

The average P/S ratio for WGS's competitors is 2.04, providing a benchmark for relative valuation. GeneDx Holdings Corp Corp (WGS) exhibits a P/S ratio of 8.26, which is 305.87% above the industry average. Given its robust revenue growth of 45.63%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Concentra Group Holdings Parent Inc

Brightspring Health Services Inc

Option Care Health Inc

Performance Decomposition

Market capitalization of WGS increased by 305.42% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 550.64 to 2.67K.

The secondary factor is the Revenue Growth, contributed 45.63%to the performance.

Overall, the performance of WGS in the past 1 year is driven by P/E Change. Which is more unsustainable.

45.63%

70.51M → 102.69M

Revenue Growth

-125.45%

-41.37 → 10.53

Margin Expansion

385.24%

550.64 → 2.67K

P/E Change

305.42%